title: Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.
abstract: BACKGROUND
  Thrombotic thrombocytopenic purpura is an uncommon disease with a high mortality rate even with current treatment. The cause of the syndrome and its optimal treatment are unknown. Although both plasma exchange and plasma infusion have been useful treatments, it is not clear which is superior. In this report we describe a prospective randomized trial comparing plasma exchange with plasma infusion for the treatment of thrombotic thrombocytopenic purpura.
  
  
  METHODS
  One hundred two patients with thrombotic thrombocytopenic purpura were randomly assigned to receive either plasma exchange or plasma infusion with fresh-frozen plasma on seven of the first nine days after entry into the trial. The total volume of plasma received by patients undergoing plasma exchange was three times that received by patients undergoing plasma infusion. All the patients also received aspirin and dipyridamole. The outcomes in the two groups were compared at the end of the first treatment cycle (day 9) and after six months.
  
  
  RESULTS
  At the end of the first treatment cycle patients receiving plasma exchange had a higher rate of response as defined by an increase in the platelet count (24 of 51 patients) than those who received plasma infusion (13 of 51, P = 0.025). Of the 51 patients treated with plasma exchange, 2 died, whereas 8 of the 51 patients who received plasma infusion died (P = 0.035). After six months the outcome in the plasma-exchange group was still superior, with a response observed in 40 of 51 patients, whereas 25 of 51 patients in the plasma-infusion group responded (P = 0.002). Eleven patients in the plasma-exchange group died, as did 19 patients in the plasma-infusion group (P = 0.036). The overall mortality was 29 percent.
  
  
  CONCLUSIONS
  Plasma exchange is more effective than plasma infusion in the treatment of thrombotic thrombocytopenic purpura.
authors.affiliation: Department of Medicine, University of Ottawa, Ont., Canada.
authors.forename: G A
authors.initials: GA
authors.lastname: Rock
authors.forename: K H
authors.initials: KH
authors.lastname: Shumak
authors.forename: N A
authors.initials: NA
authors.lastname: Buskard
authors.forename: V S
authors.initials: VS
authors.lastname: Blanchette
authors.forename: J G
authors.initials: JG
authors.lastname: Kelton
authors.forename: R C
authors.initials: RC
authors.lastname: Nair
authors.forename: R A
authors.initials: RA
authors.lastname: Spasoff
mesh_terms: D000328:Adult; D001241:Aspirin / Q000627:therapeutic use; D001803:Blood Transfusion; D004176:Dipyridamole / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008991:Monitoring, Physiologic; D010949:Plasma; D010951:Plasma Exchange; D010976:Platelet Count; D011446:Prospective Studies; D011697:Purpura, Thrombotic Thrombocytopenic / Q000097:blood / Q000401:mortality / Q000628:therapy*
chemical_list: D004176:Dipyridamole; D001241:Aspirin